Phase 2 LEGATO-HD Study: Laquinimod Significantly Lowers Caudate Volume.

Published Date: 18 Feb 2024

Further research into laquinimod or other immune-modulating therapies may be necessary in light of the positive safety profile and the recognition of the unmet therapeutic needs in Huntington disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Common intracellular toxin could help fight leukemia

2.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

3.

Scholastic performance is a key concern for young cancer patients, study finds

4.

AACR: American Association for Cancer Research

5.

Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot